Overview
Cybin is a clinical-stage biopharmaceutical company developing proprietary psychedelic-based therapeutics, with lead programs targeting major depressive disorder using deuterated psilocybin analogs engineered for improved pharmacokinetics. Their CYB003 and CYB004 molecules are designed to provide more predictable and shorter therapeutic sessions.
More in Psychedelics
Latest industry news
China Performs World's First Commercial BCI Implant, Marking a Pivotal Moment in the Global Brain-Computer Interface Race
2026-07-16 · Industry
NIH Confirms Brain-Computer Device Restores Speech in Human Patient
2026-07-15 · Research
Neurovalens Wins FDA Approval for Wearable PTSD Therapy Aimed at US Veterans
2026-07-14 · Policy
BRYM Raises €650K to Build Wearable Neurofeedback Platform for Consumer and Clinical Markets
2026-07-13 · Funding
Company details
Category
🍄 Psychedelics
Location
Toronto, Canada
Funding
Public · NYSE American: CYBN
Website
www.cybin.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →